Literature DB >> 11809124

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.

A Stewart1, J Sandercock, S Bryan, C Hyde, P M Barton, A Fry-Smith, A Burls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11809124     DOI： 10.3310/hta5020

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  12 in total

1.  Riluzole for motor neurone disease. More trials are needed.

Authors:  J Sandercock; A Burls; C Hyde; A Fry-Smith; P Barton; S Bryan; A Stewart
Journal:  BMJ       Date:  2001-05-26

Review 2.  Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

Authors:  Alan Moore; Carolyn A Young; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

3.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Michael E Bozik; Evan W Ingersoll; Robert Miller; Hiroshi Mitsumoto; Jeremy Shefner; Dan H Moore; David Schoenfeld; James L Mather; Donald Archibald; Mary Sullivan; Craig Amburgey; Juliet Moritz; Valentin K Gribkoff
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

Review 4.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  Robert G Miller; J D Mitchell; Dan H Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 5.  Review of the History of Non-traumatic Spinal Cord Dysfunction.

Authors:  Peter Wayne New; Fin Biering-Sørensen
Journal:  Top Spinal Cord Inj Rehabil       Date:  2017

6.  A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.

Authors:  Xiaohua Xu; Aleksandar Denic; Luke R Jordan; Nathan J Wittenberg; Arthur E Warrington; Bharath Wootla; Louisa M Papke; Laurie J Zoecklein; Daehan Yoo; Jonah Shaver; Sang-Hyun Oh; Larry R Pease; Moses Rodriguez
Journal:  Dis Model Mech       Date:  2015-05-28       Impact factor: 5.758

7.  The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice.

Authors:  René Günther; Kim-Ann Saal; Martin Suhr; David Scheer; Jan Christoph Koch; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  Front Neurosci       Date:  2014-10-07       Impact factor: 4.677

8.  Administration of 4-(α-L-rhamnosyloxy)-benzyl isothiocyanate delays disease phenotype in SOD1(G93A) rats: a transgenic model of amyotrophic lateral sclerosis.

Authors:  Maria Galuppo; Sabrina Giacoppo; Renato Iori; Gina Rosalinda De Nicola; Placido Bramanti; Emanuela Mazzon
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

9.  Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset.

Authors:  René Günther; Alexander Balck; Jan C Koch; Tobias Nientiedt; Michael Sereda; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  Front Pharmacol       Date:  2017-01-31       Impact factor: 5.810

10.  Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.

Authors:  Ton Fang; Ahmad Al Khleifat; Jacques-Henri Meurgey; Ashley Jones; P Nigel Leigh; Gilbert Bensimon; Ammar Al-Chalabi
Journal:  Lancet Neurol       Date:  2018-03-07       Impact factor: 44.182
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.